GBI Research, the leading business intelligence provider, has released its latest research, "Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific". The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. https://www.reportscorner.com/reports/20856/Critical-Care-Market-to-2019---Growth-from-Factor-Concentrates-New-Indications-and-Increasing-Demand-for-Albumin-in-Asia-Pacific/

1. RC
Reports Corner
Critical Care Market to 2019 - Growth from Factor Concentrates New
Indications and Increasing Demand for Albumin in Asia-Pacific

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
GBI Research, the leading business intelligence provider, has
released its latest research, "Critical Care Market to 2019 - Growth
from Factor Concentrates New Indications and Increasing
Demand for Albumin in Asia-Pacific". The report provides in-depth
analysis of the drivers and barriers that affect the global critical
care market.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Critical Care Market to 2019 - Growth from Factor Concentrates
New Indications and Increasing Demand for Albumin in Asia-
Pacific
Summary
GBI Research, the leading business intelligence provider, has
released its latest research, "Critical Care Market to 2019 - Growth
from Factor Concentrates New Indications and Increasing
Demand for Albumin in Asia-Pacific". The report provides in-depth
analysis of the drivers and barriers that affect the global critical
care market. The report has been compiled using data and
information sourced from proprietary databases, primary and
secondary research, and in-house analysis carried out by GBI
Research's team of industry experts.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
The report analyzes the markets for factor XIII concentrates,
fibrinogen concentrates, albumins, antithrombins and
prothrombin complex concentrates in the US, the top five
countries of Europe (the UK, Germany, France, Italy and Spain),
and Japan. The report does also provide an overview on Asia-
Pacific countries, including China, India and Australia.
The report provides an overview of major marketed products in
critical care market along with treatment usage patterns, average
annual cost of therapy and market forecast to 2019 for key
geographical markets, as well as for leading therapeutic
segments. The report also provides information on the Research
and Development (R&D) product pipeline and explores the
competitive landscape, including the provision of profiles for
major players in the critical care market. Finally, the report
includes analysis of Mergers and Acquisitions (M&A) activity in
the critical care market.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
GBI Research's analysis indicates that the global critical care
market is still an untapped market, with a small number of players
accounting for a major proportion of the overall market. The
market grew at a very slow growth rate between 2006 and 2012,
possibly due to the lac of availability of many of the products in
certain markets, especially in the US.
GBI Research estimates that the overall critical care therapeutics
market was worth $2.3 billion in 2012, having grown in size at a
CAGR of 11% from $1.2 billion in 2006. The market is expected to
grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-
digit market growth registered between 2006 and 2012 can be
attributed primarily to the increased demand for and cost of
albumin, as well as the approval and launch of new products.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
The growth of the overall critical care market during the forecast
period is expected to be largely due to an increasing preference in
the market for factor concentrates such as Riastap, Corifact, rFXIII
(which has been launched in the EU and is expected to be
launched in the US later this year), the expanded indication for
Antithrombin (AT) III and factor concentrates, and rising demand
for albumin from countries in the Asia-Pacific region. Stagnant
innovations, a low prevalence rate and the consequent limited
availability of patients are some of the factors impeding the
growth of the critical care market.
Scope
- Data and analysis regarding the critical care market in leading
geographical locations – the US, the UK, Germany, France, Italy,
Spain, and Japan and Asia-Pacific countries, including India,
China and Australia.

7. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Annualized market data for the critical care market, including the
individual markets for factor XIII concentrate, fibrinogen
concentrate, antithrombin, prothrombin complex concentrate and
albumin from 2006 to 2012, with forecasts provided up to 2019.
- Market data on the geographical landscape and therapeutic
landscape, including market size, market share, cost of therapy,
sales volume, and treatment usage patterns, such as disease
population, diagnosis population and prescription population.
- Key drivers and restraints that have had a major impact upon the
market.
- An overview of the competitive landscape of the global critical
care market, including benchmarking for leading companies.
Some of the key companies studied in this report are CSL,
Octapharma, Baxter, Grifols, and LFB.
- Key M&A activities that took place in 2010 and 2011 in the critical
care market.

8. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Align company product portfolios to markets with high growth
potential.
- Build effective strategies to launch pipeline products, by
identifying potential geographical markets.
- Exploit in-licensing and out-licensing opportunities by
identifying products that might fill portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of
top competitors.
- Devise a more tailored country strategy through the
understanding of key drivers and barriers and market potential of
each indication.
- Develop market-entry and market expansion strategies by
identifying the geographic markets poised for strong growth.

9. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Reinforce R&D pipelines by identifying new target mechanisms
capable of producing first-in-class molecules which are safer and
more efficacious

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Critical Care Market to 2019 – Global Overview 11
4 Critical Care Market to 2019 – Geographical Landscape 13
4.1 Introduction 13
4.2 The US – Critical Care Market 14
4.2.1 Revenue 14
4.3 Top Five European Countries – Critical Care Market 16
4.3.1 Revenue 16
4.4 Japan – Critical Care Market 18
4.4.1 Revenue 18
5 Critical Care Market to 2019 – Albumin Market 19

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
5.1 Introduction 19
5.2 Marketed Albumin Products 21
5.2.1 Buminate 21
5.2.2 Zenalb 21
5.2.3 Human Albumin Biotest 21
5.2.4 AlbuRx 22
5.2.5 Albuminar 22
5.2.6 Albutein 22
5.2.7 Albuked 23
5.2.8 Vialebex 23
5.2.9 Albunorm 23
5.2.10 AlbuRAAS 23
5.3 Revenue 24
5.4 Cost of Therapy 26
5.5 China 27

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
5.5.1 Introduction 27
5.5.2 Strict Regulatory Reforms Leading to Tighter Supply 27
5.5.3 Fragmented Market Dominated by Overseas Players 27
5.5.4 Price of Albumin Likely to Remain High 27
5.5.5 Conclusion 28
5.6 India 28
5.7 Australia 28
5.7.1 Introduction 28
5.7.2 Rising Albumin Demand 29
5.7.3 Australian Albumin Market 29
5.8 Market Drivers and Barriers 30
5.8.1 Market Drivers 30
5.8.2 Market Barriers 31
6 Critical Care Market to 2019 – Antithrombin Concentrate Market 32
6.1 Introduction 32

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
6.1.1 Marketed Antithrombin Concentrate Products 33
6.1.2 Revenue 38
6.1.3 Geographical Segmentation 40
6.1.4 Cost of Treatment 42
6.1.5 Treatment Usage Pattern 43
6.2 Drivers and Restraints 45
6.2.1 Drivers 45
6.2.2 Restraints 46
7 Critical Care Market to 2019 – Fibrinogen Concentrate Market 47
7.1 Introduction 47
7.2 Marketed Fibrinogen Concentrates 48
7.2.1 Haemocomplettan/Riastap 48
7.2.2 Clottafact 48
7.2.3 Other Marketed Fibrinogen Concentrates 49
7.2.4 Revenue 49

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
7.2.5 Geographical Segmentation 51
7.3 Market Segmentation 53
7.3.1 Cost of Treatment 55
7.4 Treatment Usage Pattern 56
7.5 Drivers and Barriers 59
7.5.1 Drivers 59
7.5.2 Barriers 60
8 Critical Care Market to 2019 – Prothrombin Complex Concentrate Market 61
8.1 Introduction 61
8.2 Marketed Products 63
8.2.1 Beriplex P/N 63
8.2.2 Confidex 63
8.2.3 Profilnine SD 63
8.2.4 Uman Complex DI 64
8.2.5 Kaskadil 64

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
8.2.6 Octaplex 500 64
8.2.7 Cofact 64
8.2.8 Feiba VH 64
8.2.9 Bebulin VH 65
8.3 Revenue 65
8.3.1 Revenue Breakdown 67
8.4 Geographical Segmentation 68
8.5 Cost of Therapy 69
8.5.1 Treatment Usage Pattern 71
8.6 Drivers and Restraints 72
8.6.1 Drivers 72
8.6.2 Barriers 73
9 Critical Care Market to 2019 – Factor XIII Concentrate Market 74
9.1 Introduction 74
9.2 Marketed Products 75

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
9.2.1 Fibrogammin / Corifact 75
9.3 Revenue 76
9.3.1 Geographical Segmentation 78
9.3.2 Cost of Treatment 81
9.3.3 Treatment Usage Pattern 83
9.4 Drivers and Restraints 85
9.4.1 Drivers 85
9.4.2 Restraint 86
10 Critical Care Market to 2019 – Research and Development Product Pipeline 87
10.1 Introduction 87
10.1.1 rFXIII (NovoThirteen) 89
11 Critical Care Market to 2019 – Competitive Landscape 90
11.1 CSL Limited 90
11.2 Baxter International Incorporated 90
11.3 Grifols, SA 90

17. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
11.4 Octapharma AG 90
11.5 Kedrion SpA 91
11.6 Biotest 91
11.7 Laboratoire Français de Fractionnement et de Biotechnologies 91
11.8 Bio Products Laboratory Limited 91
11.9 Sanquin Blood Supply Foundation 91
11.10 China Biologic Products, Incorporated 92
11.11 Hualan Biological Engineering, Incorporated 92
11.12 Shanghai RAAS Blood Products Company, Limited 92
12 Critical Care Market to 2019 – Strategic Consolidation 93
12.1 Grifols Acquisition of Talecris Biotherapeutics in June 2011 93
12.2 LFB Biotechnologies Acquisition of GTC Biotherapeutics in December 2010 93
12.3 ViroPharma Expands Licensing Agreement with Sanquin Blood Supply Foundation in January 2010
94
13 Critical Care Market to 2019 – Appendix 95
13.1 Market Definitions 95

18. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
13.2 Abbreviations 95
13.3 Bibliography 96
13.4 Research Methodology 98
13.4.1 Coverage 98
13.4.2 Secondary Research 98
13.4.3 Primary Research 99
13.5 Therapeutic Landscape 99
13.5.1 Market 101
13.6 Geographical Landscape 102
13.7 Pipeline Analysis 102
13.8 Competitive Landscape 102
13.8.1 Expert Panel Validation 102
13.9 Contact Us 102
13.10 Disclaimer 102

19. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/20856/Critical-Care-Market-to-2019---Growth-
from-Factor-Concentrates-New-Indications-and-Increasing-Demand-for-Albumin-in-
Asia-Pacific/

20. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com